PHARMA SOLUTIONS
Smarter imaging solutions for faster clinical trials
We offer proprietary biomarkers focused on the identification and monitoring of disease in clinical trials, delivered as a turn-key medical imaging solution via a secure, cloud-based software as a service (SaaS).
Our Focus Areas
Body Composition
Body composition analysis offers insights into the quality of weight loss and patient health. These powerful tools support decision-making in drug development across a broad spectrum of clinical trials (i.e. obesity, neuromuscular disorders, cancer cachexia).
Cardiometabolic
Multi-organ services delivered through quantitative MRI and DXA to support obesity, metabolic, and neuromuscular disease-focused clinical trials.
MASLD/MASH & Cirrhosis
Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.
Autoimmune Disease
Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.
Gastrointestinal Disease
Rapid, high-quality sample processing with a fully digitized reporting workflow and quantitative AI-pathology.
Oncology Solutions
Integrated analysis of our noninvasive, multi-organ & tumor characterization software, digital pathology, and endoscopy, enables a deeper rapid analysis of the patient and their cancer.
Our Experience and Network
1200+
Locations Worldwide
100+
Research Partners
90+
Papers Published
75+
Interventional Trials
40,000+
Trial Datasets Processed
Case Studies
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
R. Loomba, M.L. Hartman, E.J. Lawitz, R. Vuppalanchi, J. Boursier, E. Bugianesi, M. Yoneda, C. Behling, O.W. Cummings, Y. Tang, B. Brouwers, D.A. Robins, A. Nikooie, M.C. Bunck, A. Haupt, and A.J. Sanyal, for the SYNERGY-NASH Investigators*
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
R. Loomba, Arun J. Sanyal, Kris V. Kowdley, Deepak L. Bhatt, Naim Alkhouri, Juan P. Frias, Pierre Bedossa, Stephen A. Harrison, Donald Lazas, Robert Barish, Mildred D. Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, and Manal F. Abdelmalek
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Stephen A. Harrison, Sarah K. Browne,John J. Suschak,Shaheen Tomah, Julio A. Gutierrez, Jay Yang, M. Scot Roberts, M. Scott Harris
AWS Health Innovation Podcast
In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, Principal Healthcare and Life Sciences Startups Business Development Manager at Amazon Web Services, sits down with Rajarshi Banerjee, aka ‘Banjo’, the CEO of, a company revolutionizing the way we diagnose and monitor chronic diseases.
Listen on Healthpodcastnetwork.comConference Schedule 2025
Come visit us at one of the conferences listed to discuss your trial requirements
Keystone Trajectories to Heart Failure: Immunometabolic Mechanisms
European Crohn's and Colitis Organisation (ECCO)
Keystone MASH Pathogenesis and therapeutic approaches
AASLD - Emerging Topic Conference: Precision Medicine in MASLD
Global Congress on Nephrology and Urology
European Association for the Study of the Liver (EASL)
3rd Precision Medicine for IBD Summit
Obesity & Weight Loss Drug Development Summit
American Diabetes Association (ADA)
26th Global, Nephrology, Urology and Kidney Failure Congress
ESC (European Society of Cardiology Congress)
European Association for the Study of Diabetes (EASD)
MASH and Obesity Summit
UEG Week (United European Gastroenterology)
American Society of Nephrology Kidney Week
American Association for the Study of Liver Diseases (AASLD)
American Heart Association
